Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Surein Arulananda

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2025
Brief Report: Alectinib with salvage platinum-taxane chemotherapy in a pregnant woman with ALK-rearranged NSCLC and rapid disease progression followed by a successful pregnancyRichard Pham, Daniel Garama, Atul Malhotra, et al.
Translational Lung Cancer Research|July 8, 2024
Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma based on real-world cumulative clinical dataSheng Lu, Aotian Guo, Haichuan Hu, et al.
Cell Death Discovery|May 29, 2021
A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesotheliomaSurein Arulananda, Megan O'Brien, Marco Evangelista, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2025
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II TrialAdithya Balasubramanian, Claire Marceaux, Sehrish Kanwal, et al.
Drug Design, Development and Therapy|April 8, 2020
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in AustraliaJason D Lickliter, Hui K Gan, Mark Voskoboynik, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 30, 2023
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMesoNicholas McNamee, Catriona Harvey, Lauren Gray, et al.
Cell Death & Disease|April 26, 2019
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survivalErinna F Lee, Tiffany J Harris, Sharon Tran, et al.
Cell Death Discovery|December 10, 2020
BCL-XL is an actionable target for treatment of malignant pleural mesotheliomaSurein Arulananda, Megan O'Brien, Marco Evangelista, et al.
Lung Cancer (Amsterdam, Netherlands)|June 28, 2026
Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1)Malinda Itchins, Marliese Alexander, Steven Kao, et al.
Cell Death Discovery|June 16, 2021
Correction: BCL-XL is an actionable target for treatment of malignant pleural mesotheliomaSurein Arulananda, Megan O'Brien, Marco Evangelista, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2025
Brief Report: Alectinib with salvage platinum-taxane chemotherapy in a pregnant woman with ALK-rearranged NSCLC and rapid disease progression followed by a successful pregnancyRichard Pham, Daniel Garama, Atul Malhotra, et al.
Translational Lung Cancer Research|July 8, 2024
Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma based on real-world cumulative clinical dataSheng Lu, Aotian Guo, Haichuan Hu, et al.
Cell Death Discovery|May 29, 2021
A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesotheliomaSurein Arulananda, Megan O'Brien, Marco Evangelista, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2025
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II TrialAdithya Balasubramanian, Claire Marceaux, Sehrish Kanwal, et al.
Drug Design, Development and Therapy|April 8, 2020
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in AustraliaJason D Lickliter, Hui K Gan, Mark Voskoboynik, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 30, 2023
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMesoNicholas McNamee, Catriona Harvey, Lauren Gray, et al.
Cell Death & Disease|April 26, 2019
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survivalErinna F Lee, Tiffany J Harris, Sharon Tran, et al.
Cell Death Discovery|December 10, 2020
BCL-XL is an actionable target for treatment of malignant pleural mesotheliomaSurein Arulananda, Megan O'Brien, Marco Evangelista, et al.
Lung Cancer (Amsterdam, Netherlands)|June 28, 2026
Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1)Malinda Itchins, Marliese Alexander, Steven Kao, et al.
Cell Death Discovery|June 16, 2021
Correction: BCL-XL is an actionable target for treatment of malignant pleural mesotheliomaSurein Arulananda, Megan O'Brien, Marco Evangelista, et al.
Pageof 5